TP53 and endometrial cancer: The TP53 mutation c.733G>A (p.Gly245Ser), which disrupts the DNA-binding domain of the TP53 protein, aligns with existing literature that links TP53 mutations to poor prognosis and resistance to therapy in various cancers, including endometrial cancer [24].